AFP and neoplasm: A chi-squared test comparing groups of patients who survived for <12 months and those who survived for ≥12 months showed that the following characteristics were associated with decreased 12-month survival rates (P < 0.001; Table 2): BCLC stage D disease classification, Child–Pugh class C, MELD score ≥10, serum AFP level ≥1000 ng/mL, poor performance status, moderate-to-severe ascites, multiple tumors, large tumor size (≥5 cm), and portal vein invasion.